Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Angela Maria Fulgenzi

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Hepatology (Baltimore, Md.)|May 23, 2022
ReplyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, David J Pinato
Hepatology (Baltimore, Md.)|May 3, 2022
ReplyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, David J Pinato
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2025
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular CancerDavid J Pinato, Pasquale Lombardi, Antonio D'Alessio, et al.
Expert Opinion on Investigational Drugs|May 4, 2022
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?Claudia Angela Maria Fulgenzi, Antonio D'Alessio, Olabisi Ogunbiyi, et al.
Chemotherapy|January 9, 2022
New Frontiers in the Medical Therapy of Hepatocellular CarcinomaClaudia Angela Maria Fulgenzi, Antonio D'Alessio, Thomas Talbot, et al.
Expert Review of Molecular Diagnostics|March 3, 2022
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinomaAmbreen Muhammed, Antonio D'Alessio, Andrei Enica, et al.
Journal of Bone Oncology|March 21, 2022
Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumorsClaudia Angela Maria Fulgenzi, Andrea Napolitano, Eliodoro Faiella, et al.
Current Drug Metabolism|September 22, 2020
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver CirrhosisGiovanni Galati, Antonio Fabio Massimo Vainieri, Claudia Angela Maria Fulgenzi, et al.
Frontiers in Endocrinology|November 22, 2019
Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment NomogramsAlessandro Scoppola, Lidia Strigari, Agnese Barnabei, et al.
Oncotarget|March 25, 2020
Prognostic and predictive factors in pancreatic cancerEmanuela Dell'Aquila, Claudia Angela Maria Fulgenzi, Alessandro Minelli, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Hepatology (Baltimore, Md.)|May 23, 2022
ReplyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, David J Pinato
Hepatology (Baltimore, Md.)|May 3, 2022
ReplyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, David J Pinato
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2025
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular CancerDavid J Pinato, Pasquale Lombardi, Antonio D'Alessio, et al.
Expert Opinion on Investigational Drugs|May 4, 2022
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?Claudia Angela Maria Fulgenzi, Antonio D'Alessio, Olabisi Ogunbiyi, et al.
Chemotherapy|January 9, 2022
New Frontiers in the Medical Therapy of Hepatocellular CarcinomaClaudia Angela Maria Fulgenzi, Antonio D'Alessio, Thomas Talbot, et al.
Expert Review of Molecular Diagnostics|March 3, 2022
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinomaAmbreen Muhammed, Antonio D'Alessio, Andrei Enica, et al.
Journal of Bone Oncology|March 21, 2022
Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumorsClaudia Angela Maria Fulgenzi, Andrea Napolitano, Eliodoro Faiella, et al.
Current Drug Metabolism|September 22, 2020
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver CirrhosisGiovanni Galati, Antonio Fabio Massimo Vainieri, Claudia Angela Maria Fulgenzi, et al.
Frontiers in Endocrinology|November 22, 2019
Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment NomogramsAlessandro Scoppola, Lidia Strigari, Agnese Barnabei, et al.
Oncotarget|March 25, 2020
Prognostic and predictive factors in pancreatic cancerEmanuela Dell'Aquila, Claudia Angela Maria Fulgenzi, Alessandro Minelli, et al.
Pageof 4